Evidence map›Paper›PMID 36332964›Full record

ArticleBMJ open2022

Investigating the association between IL-6 antagonist therapy and blood coagulation in critically ill patients with COVID-19: a protocol for a prospective, observational, multicentre study.

Emőke Henrietta Kovács, Máté Rottler, Fanni Dembrovszky, Klementina Ocskay, László Szabó, Péter Hegyi, Zsolt Molnár, Krisztián Tánczos

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05218369 (Effects of Immunomodulation With Interleukin-6 Antagonists on the Coagulation System in Critically-ill Covid-19 Patients), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05218369 unknown statusnot on this map

Effects of Immunomodulation With Interleukin-6 Antagonists on the Coagulation System in Critically-ill Covid-19 Patients

TypeobservationalSponsorUniversity of PecsRan2022 to 2024Enrolled30ConditionsCOVID-19, Critical IllnessArmsIL6 Antagonist
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Emőke Henrietta KovácsCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.ORCID 0000-0002-6417-2296
Máté RottlerSzent György University Teaching Hospital of Fejér County, Székesfehérvár, Hungary.
Fanni DembrovszkyCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Klementina OcskayCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.ORCID 0000-0001-5848-2506
László SzabóCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Péter HegyiCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.ORCID 0000-0003-0399-7259
Zsolt MolnárCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.ORCID 0000-0002-1468-4058
Krisztián TánczosDepartment of Anaesthesiology and Intensive Therapy, Semmelweis University, Budapest, Hungary tkrisztian78@gmail.com.
Semmelweis University · HUFejér Megyei Szent György Egyetemi Oktató Kórház · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHypercoagulation is one the main features of COVID-19. It is induced by the hyperinflammatory response that shifts the balance of haemostasis towards pro-coagulation. Interleukin-6 (IL-6) antagonist therapy has been recommended in certain subgroups of critically ill patients with COVID-19 to modulate inflammatory response. The interaction between immune response and haemostasis is well recognised. Therefore, our objective is to evaluate whether the modulation of the inflammatory response by IL-6 antagonist inflicts any changes in whole blood coagulation as assessed by viscoelastic methods in critically ill patients with COVID-19. METHODS AND ANALYSIS: In this prospective observational study, we are going to collect data on inflammatory parameters and blood coagulation using the ClotPro ETHICS AND DISSEMINATION: Ethical approval was given by the Medical Research Council of Hungary (1405-3/2022/EÜG). All participants provided written consent. The results of the study will be disseminated through peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT05218369; Clinicaltrials.gov.

Indexed as

COVID-19 Drug TreatmentBlood CoagulationCritical IllnessHumansInterleukin-6Multicenter Studies as TopicObservational Studies as TopicProspective StudiesInterleukin-6Adult intensive & critical careBleeding disorders & coagulopathiesCOVID-19

Identifiers

PMID36332964
PMCPMC9638747
OpenAlexW4308196285

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.